Generation of induced pluripotent stem cell line (KRIBBi004-A) from adult bone marrow CD34+ cells from a patient carrying 46,XX,t(1;5)(p31.1;35.1) karyotype

Hyebin Koh; Soon-Young Kwon; Xing Zhen; Hye-Yeong Ha; Jong-Hee Lee

doi:10.1016/j.scr.2021.102587

Generation of induced pluripotent stem cell line (KRIBBi004-A) from adult bone marrow CD34⁺ cells from a patient carrying 46,XX,t(1;5)(p31.1;35.1) karyotype

Stem Cell Res. 2021 Dec:57:102587. doi: 10.1016/j.scr.2021.102587. Epub 2021 Oct 26.

Authors

Hyebin Koh¹, Soon-Young Kwon², Xing Zhen³, Hye-Yeong Ha⁴, Jong-Hee Lee⁵

Affiliations

¹ Futuristic Animal Resource & Research Center (FARRC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of Korea; Department of Functional Genomics, KRIBB School of Bioscience, University of Science and Technology (UST), Daejeon, Republic of Korea.
² National Primate Research Center (NPRC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of Korea.
³ National Primate Research Center (NPRC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of Korea; Department of Nanoscience and Nanotechnology, Graduate School, Kyungpook National University, Daegu 41566, Republic of Korea.
⁴ Division of Intractable Disease Research, Korea National Institute of Health, Cheongju, Republic of Korea. Electronic address: hahy0130@korea.kr.
⁵ National Primate Research Center (NPRC), Korea Research Institute of Bioscience and Biotechnology (KRIBB), Cheongju, Republic of Korea; Department of Functional Genomics, KRIBB School of Bioscience, University of Science and Technology (UST), Daejeon, Republic of Korea. Electronic address: jonglee@kribb.re.kr.

PMID: 34736040
DOI: 10.1016/j.scr.2021.102587

Abstract

Induced pluripotent stem cell (iPS) technology may be advantageous for the study of genetic aberrations in terms of recapitulating the full manifestation of pathological features in vitro, identifying underlying pathways, and developing personalized therapeutics rather than procuring somatic cells from patients. Here, we derived an iPSC line from a patient with reciprocal chromosome translocation, t(1;5)(p31.1;35.1), as a novel alternative model to identify clinical phenotypes induced by genetic instability. The resulting iPSC line generated from somatic cells with an existing instability showed representative characteristics of PSCs, and might serve as an unparalleled cellular resource for the development of a custom remedy.